FBXW7 promotes osteoarthritis injury by regulating SLC7A11 ubiquitination degradation and chondrocyte ferroptosis.

Rhapontigenin inhibits inflammation and senescence of chondrocytes from patients with osteoarthritis by targeting INHBA.

Total knee radiomic feature atlas derived from magnetic resonance imaging segmentation: Insights into osteoarthritis incidence predictors.

Environmental pollutants as emerging risk factors in osteoarthritis: Mechanistic and epidemiological evidence.

CircP4HA3/miR-5001-5p/THBS2 axis promotes chondrocyte senescence and cartilage degradation during osteoarthritis progression.

Microbial metabolite tigloside alleviates osteoarthritis by repolarizing macrophages from M1 to M2 phenotype through Trafd1 destabilization and Trafd1-mediated NF-κB/STAT6 signaling pathways.

Dry cupping therapy has no effect on pain, function, or quality of life in women with knee osteoarthritis: Randomized placebo-controlled trial.

Introduction: In today’s world, pharmacological, biochemical, and surgical treatments often fall short in effectively managing Osteoarthritis (OA). However, Ayurveda has suggested various therapies for its long-term efficacy, and Herbal Poultice is one among them. It is seen to provide analgesic and antiinflammatory effects. The goal of the study was to evaluate the effectiveness of herbal poultice as a natural and supportive treatment option for knee OA. Aim: The study’s main aim was to evaluate Punarnavadi Upanaha Sweda’s efficacy in managing Janusandhigatavata, using daily poultice bandaging on the affected knee for upto seven days. Materials and Methods: The present single arm clinical trial was conducted at Dr. DY Patil College of Ayurved Hospital and Research Centre Pimpri, Pune, Maharashtra, India, from April 2023 to October 2024. A total of 32 patients diagnosed with knee OA were included, and patients who had other joint disorders or permanent joint damage were excluded. Patients were also excluded if the patient had other joint disorders or permanent joint damage. The intervention consisted of Punarnavadi Upanaha Sweda, a poultice applied externally to the affected knee joint for six hours daily over seven consecutive days, preceded by a five-minute massage. Followup assessments were conducted on the 14th day after the last treatment. Demographic parameters, including age, gender, and baseline pain levels, were recorded for all participants. To assess the effects of the treatment, joint pain was measured using the Visual Analog Scale (VAS), and joint restrictions were evaluated through goniometric measurements of the knee’s range of motion. Statistical analysis was performed using the Friedman test for follow-up and the Wilcoxon signed rank test for before and after assessment, and a p-value of less than 0.05 was considered statistically significant. Results: The subjective parameter viz., Janusandhishool (Pain), Janusandhishotha (swelling), Akunchana Prasarana Kashtata (joint restriction) related to the knee joint and objective parameter viz., VAS for the pain of the knee joint and goniometric measurement for the restricted knee joint movements were statistically significant (p<0.05), indicating a significant improvement from baseline assessment to the end of treatment. Conclusion: The study provides strong evidence for the effectiveness of Punarnavadi Upanaha Sweda in managing knee OA, demonstrating significant improvements in both joint pain and range of motion. These findings suggest that this Ayurvedic treatment can be a valuable option for alleviating symptoms and improving the quality of life in patients with knee OA.

Nystose mitigates mono sodium iodoacetate-induced knee osteoarthritis by inhibiting the NLRP3 Inflammasome.

Knee osteoarthritis is hallmarked by pain and structural changes, impacting biomechanical function. However, the interplay between pain and biomechanics is poorly understood. Experimental knee pain may act as a surrogate model of clinical pain to study potential changes in pain mechanisms and biomechanics. This randomised, controlled crossover study induced knee pain with hypertonic saline (7%) injected into the infrapatellar fat pad, controlled by isotonic saline (0.9%) injections. Gait biomechanics (speed, braking impulse, propulsion impulse) were measured using motion capture. Cuff-pressure algometry estimated pressure pain and tolerance thresholds (PPT and PTT), temporal summation of pain and conditioned pain modulation. Sleep, depression, anxiety, pain catastrophizing and pain were assessed by questionnaires. Thirty-four young, healthy participants had a mean peak pain of 58 (0-100) after the hypertonic saline injection. Changes in PPT (F(2,62) = 8.0, p < 0.001) and propulsion impulse (F(1.8,50.0) = 1.79, p = 0.039) were observed after pain induction. Multiple linear regression revealed that a combination of baseline PPT, depression scores, speed and propulsion impulse explained 38.7% of the variability in peak knee pain (F(4,29) = 4.6, p < 0.01), while a combination of PTT, speed, braking and propulsion impulse measured during experimental pain explained 57.4% (F(4,29) = 9.8, p < 0.001) of the variability. Changes in PPTs and propulsion impulse were observed after the knee pain induction. Peak knee pain variability can be partly explained using a combination of biomechanics, pain sensitivity and cognitive factors. This forms the basis for a targeted clinical evaluation of patients. Knee osteoarthritis has been increasingly recognised as a multifactorial condition influenced by, for example, cognitive factors and pain sensitivity. This study demonstrated an experimental pain model that mimicked clinical pain experienced by people with moderate-to-severe OA pain. Additionally, this study provides novel insights into the interplay between pain sensitivity, biomechanics and cognitive factors and experimental knee pain.

Background: Osteoarthritis (OA) is a prevalent and debilitating chronic disease for which there are currently no approved disease-modifying osteoarthritis drugs (DMOADs). While mesenchymal stem cells (MSCs) have emerged as promising DMOAD candidates, their clinical application is hindered by inconsistent in vivo efficacy and an incomplete understanding of the underlying pathological mechanisms and therapeutic targets. Methods: To address these limitations, we developed a novel therapeutic strategy by conjugating MSCs with steroid-loaded gold nanostars (MSC-Au-Steroid). The effects of MSC-Au-Steroid were assessed in vitro using osteoarthritis patient-derived chondrocytes and peripheral blood mononuclear cells (PBMCs), and in vivo using a monosodium iodoacetate (MIA)-induced mouse model of osteoarthritis. Key assessments included anti-inflammatory activity, metabolic profiling (glycolysis and oxidative phosphorylation), mitochondrial function, reactive oxygen species (ROS) production, mTOR signaling, and immunomodulatory effects on Th1, Th17, and regulatory T cells (Tregs). Results: MSC-Au-Steroid demonstrated strong anti-inflammatory effects in OA chondrocytes, promoted cartilage regeneration, and normalized altered metabolic profiles under inflammatory conditions. It improved mitochondrial function and suppressed excessive ROS production via mTOR signaling regulation. In vivo, MSC-Au-Steroid alleviated clinical symptoms and preserved cartilage integrity in the MIA-induced OA mouse model. Furthermore, it exhibited immunomodulatory effects in both mouse and patient-derived PBMCs, inhibiting Th1 and Th17 responses while promoting Treg induction and restoring immune tolerance. Conclusions: MSC-Au-Steroid represents a promising multifactorial therapeutic candidate for OA by targeting both metabolic reprogramming and immune modulation. These findings provide strong evidence that MSC-Au-Steroid acts as a disease-modifying agent, addressing multiple pathological factors and offering superior efficacy compared to current therapies.

Forsythoside B protects cartilage and subchondral bone in osteoarthritis by regulating the Nrf2/NF - κ B signaling pathway.

Revealing early subchondral bone structural changes in osteoarthritis progression in a collagenase-induced mouse model using microCT.

Pharmacological inhibition of PGK1 by genipin reduces inflammation and oxidative damage in osteoarthritis.

TinyML-enabled wearable system for early detection of knee osteoarthritis using ensemble gait classification.

Low-Dose Radiotherapy for Osteoarthritis: Current Evidence, Practical Recommendations and Future Perspectives.

Recent advances in intra-articular bioactive delivery for the treatment of osteoarthritis.

Bibliometric analysis of mesenchymal stem cell-derived extracellular vesicles in the treatment of osteoarthritis.

Immunomodulatory cartilage tissue engineering: synergistic inflammation suppression and cartilage regeneration for osteoarthritis treatment.

Clinical and demographic features of patients with occlusal dysesthesia: a retrospective cross‑sectional study.